Publications PAIN

2008

J. Nadstawek et al.
Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain;

D. Vondrackova et al.
Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain;

K. Smith et al.
Single-and multiple-Dose Pharmacokinetic Evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged release combination in healthy adult volunteers;
*Clinical Therapeutics* **2008**, 30, 2051-2068.

K. Simpson et al.
Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in patients with moderate-to-severe noncancer pain;
*Current Medical Research and Opinion* **2008**, 24, 3503-3512.

M. Hanna et al.
Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients
2009

W. Meissner et al.
A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation;

O. Löwenstein et al.
Combined prolonged release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain - a randomised controlled trial;
*Expert Opinion on Pharmacotherapy* 2009, 10, 531-543.

A. Rentz et al.
Validation of the Bowel Function Index to detect clinically meaningful changes following treatment with oxycodone and naloxone in opioid-induced constipation;
*Journal of Medical Economics* 2009, 12, 371-383.
2010

Sandner-Kiesling A. et al.
Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain;

Löwenstein O. et al.
Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: Results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials;
2011

Rentz A. et al.
Opioid-induced constipation: Observational, Nonintervention, Multicenter Study for Validation of the Bowel Function Index for Constipation in European Countries; Current Medical Research and Opinion 2011, 27 (1), 35–44

Überall M. et al.

Smith K et al.

Ahmedzai S et al.
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain Palliative Medicine 2011, Jan;26(1), 50-60.
2012

Smith K. et al.  
Low absolute bioavailability of oral naloxone in healthy subjects  

Dunlop W. et al.  
Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis  

Mundin GE et al.  
Validated in vitro / in vivo correlation of prolonged release oxycodone/naloxone with differing dissolution rates in relation to gastrointestinal transit times  
Expert Opinion on Drug Metabolism and Toxicology 2012, 8(12):1495-1503.
2013

Trenkwalder C. et al
Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled study with an open-label extension

REVIEWS

G. Mikus
Combining opioid agonist and antagonist as a solution for opioid-induced constipation;

K. Reimer et al.
Meeting the challenges of opioid-induced constipation in chronic pain management - a novel approach;
Pharmacology 2009, 83, 10-17.

P. Holzer et al.
Opioid-induced bowel dysfunction in cancer pain: causes, consequences and a novel approach for its management;
REVIEWS (CONT.)

Müller-Lissner S.
Opioid-induced Constipation - Mechanisms, Relevance, and Management;

Müller-Lissner S.
Fixed Combination of Oxycodone with Naloxone: a New Way to Prevent and Treat Opioid-Induced Constipation;